



UROLOGY TEST OFFERINGS



Inform Diagnostics' team of subspecialist uropathologists provide expert, definitive diagnoses. We utilize advanced, in-house testing, including comprehensive immunohistochemistry (IHC) panels, to supplement morphological evaluations of difficult cases.

| Test Offering | Test details | Organ category | Indication |
|--|---|------------------------|--|
| Prostate biopsy evaluation | Prostate biopsy evaluation, prostate cancer nomograms (Partin and Han tables) | Prostate | Prostate cancer detection |
| PINgenius | An Inform Diagnostics-developed assay combining biomarker and histological interpretation factors | Prostate | To help predict risk of prostate cancer at rebiopsy for HGPIN patients |
| PIN-ERG | Multiplex ERG, basal cell markers, and AMACR IHC | Prostate | To improve prostate cancer detection and resolve atypical diagnosis in prostate biopsies |
| PTEN & ERG IHC | Biomarkers that detect PTEN deletion and ERG gene fusions | Prostate | To improve prostate cancer risk stratification |
| Prolaris | Gene expression assay | Prostate | To personalize risk stratification |
| <i>oncotype</i> DX | Molecular genomic assay | Prostate, Bladder | To personalize risk stratification |
| Decipher | Gene expression assay | Prostate | To personalize risk stratification |
| Confirm MDx <small>for Prostate Cancer</small> | Epigenetic assay | Prostate | To address false-negative biopsy concerns |
| kn _o w error | DNA specimen provenance assay | Prostate | To verify patient identification and prevent misidentification error |
| Bladder and urinary tract biopsy evaluation | Bladder and urinary tract biopsy evaluation and staging | Bladder, Urinary Tract | Bladder and urinary tract cancer detection |
| Urine/bladder and renal pelvic wash cytology | Cytomorphologic analysis of urothelial cells | Bladder, Urinary Tract | Bladder and urinary tract cancer detection |
| UROVISION® | FISH measurement of chromosome 3, 7, 17 and loss of 9p21 in urothelial cells secreted in urine | Bladder | To improve bladder and urinary tract cancer detection complementing urine cytology |
| Testis biopsy | Histological analysis of testis biopsy | Testis | Infertility evaluation |
| Testis tumor evaluation | Complete evaluation of tumor with utilization of germ cell markers IHC when applicable | Testis | Evaluation of a mass lesion |
| Stone evaluation | Chemical analysis of stone | Kidney, Bladder | To determine chemical composition of stone |
| Renal mass biopsy evaluation | Classification of renal tumor in biopsy with application of select tumor markers panel | Kidney | To aid in treatment decision for renal mass management |
| Skin biopsy and resections | Evaluation of skin lesions affecting penis, scrotum, and perineal area | Penis, Scrotum | Evaluation of a skin lesion or mass |
| HPV genotype | In situ hybridization studies of low and high-risk HPV | Penis, Scrotum | To determine HPV risk potential |
| Second opinion service | Academic-caliber second opinions | All GU | Expert consultation on difficult cases |

To order Inform Diagnostics Urologic Pathology Services or to speak with an Inform Diagnostics representative, call

1.866.588.3280

or visit us online at InformDiagnostics.com

© 2018 Inform Diagnostics, Inc. All rights reserved. GU0030 5.18

